Respiratory Syncytial Virus Vaccine

A respiratory syncytial virus vaccine, or RSV vaccine, is a vaccine that protects against respiratory syncytial virus, which affects an estimated 64 million people and causes 160,000 deaths worldwide each year. Three RSV vaccines, Arexvy from GSK, Abrysvo from Pfizer and Mresvia from Moderna, are approved for medical use in the United States, primarily for people aged 60 and older, with Arexvy also approved in the US for people aged 50 to 59 who are at increased risk. A 2013 study led to the approval of RSV vaccines in 2023, and the work supporting their development also helped support the rapid development of COVID-19 vaccines. It is on the World Health Organization's List of Essential Medicines.